🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6 results for “Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.” Clear

  1. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infection

    phase 1 other active

    1 trial

  2. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.

    phase 1 other active

    1 trial

  3. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  4. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  5. Bioequivalence Study of Empagliflozin

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    Not applicable (submitted trial is a BE study in healthy participants)

    phase 1 other active

    1 trial

  6. Pharmacokinetic study of colistimethate sodium

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources